Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tacrolimus dosing algorithm study in kidney transplant recipients
NL-OMON46562Phase 4Active, not recruiting
- Sponsor
- Erasmus MC
- Start
- Mar 2019
- Modality
- RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of tacrolimus in kidney transplant immunosuppression, sponsored by Erasmus MC. Primary endpoint: Proportion within tacrolimus target predose concentration on day 3. Started Mar 2019; status: active, not recruiting.
02
Drugs
tacrolimus
03
Conditions
kidney transplant immunosuppression
Beyond the preview
Go deeper on NL-OMON46562.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46562.